The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial evaluating the efficacy of capeOX in elderly patients with advanced gastric cancer using geriatric assessment (TCOG GI-1601).
 
Hisashi Hosaka
No Relationships to Disclose
 
Keisho Chin
Honoraria - Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb; Ono Pharmaceutical
 
Ryohei Kawabata
No Relationships to Disclose
 
Osamu Muto
No Relationships to Disclose
 
Yoshiaki Shindo
No Relationships to Disclose
 
Naoki Nagata
No Relationships to Disclose
 
Hiroshi Yabusaki
No Relationships to Disclose
 
Hiroshi Imamura
No Relationships to Disclose
 
Shunji Endo
No Relationships to Disclose
 
Tomomi Kashiwada
Speakers' Bureau - Chugai Pharma; Lilly Japan; Taiho Pharmaceutical; Takeda
 
Masato Nakamura
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; MSD; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Jun Hihara
No Relationships to Disclose
 
Michiya Kobayashi
No Relationships to Disclose
 
Fumio Nagashima
Speakers' Bureau - Chugai Pharma; Janssen; Kyowa Hakko Kirin; Merck Serono; Ono Pharmaceutical; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Daisuke Takahari
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo/UCB Japan; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Naoki Ishizuka
Stock and Other Ownership Interests - Sanofi
Honoraria - Chordia Therapeutics; Chugai Pharma
Research Funding - Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)